Study objective-The aim was to determine if a new controlled release formulation (Oscorel) of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen has been preferentially prescribed in patients with prior history of gastrointestinal disturbances.
s prescription event monitoring studies showed that previous recipients of Osmosin had a substantially higher background incidence of dyspepsia and gastritis than recipients of other NSAIDS studied at about the same time.34 Inman suggested that the promotion of Osmosin had fostered expectations that the product had a safety advantage with respect to gastrointestinal toxicity, thereby prompting its use in patients more prone to such toxicity. Indeed, selective prescription of newly introduced NSAIDS in persons with gastrointestinal complaints seems to be a feature of antirheumatic therapy.5 6 In general, in any class of drugs, a claimed safety advantage seems likely to prompt the prescribing of the product to patients known or suspected to be at risk to the condition at issue. Termed channelling, this is a general phenomenon, not limited to NSAIDS.7 It complicates the interpretation of adverse reports. In January, 1989, SmithKline and French introduced in The Netherlands a controlled release formulation (Oscorel, Oruvail) of the established NSAID, ketoprofen.
The product has been promoted with claims that it is a significant step forward in NSAID therapy, prompting the inference that it produces fewer gastrointestinal disturbances than other products in its class. difference from the total reference group. We looked in detail at the prescribing patterns of the 200°o of the physicians who accounted for half of the recipients of Oscorel. There was no significant difference in the number of prescriptions for peptic ulcer therapy per 1000 patient days of NSAID use issued by these physicians, versus by other physicians.
We identified 771 patients who used nonOscorel forms of ketoprofen in the observation period and who were not starters. In 16 6)% of these patients a history of peptic ulcer therapy was found, a rate which was comparable with the baseline level in the reference group (RR= 1 06; 95% CI 0-90-1-24). Likewise, stratified analysis did not show any significant differences in rates of peptic ulcer therapy in Orudis users when compared with the reference group. Thus there was no evidence to suggest that the drug ketoprofen was selectively overprescribed or underprescribed to peptic ulcer therapy recipients, notwithstanding published evidence that the drug has a better gastrointestinal tolerance than indomethacin. 12 It was a conservative manoeuvre to exclude from the analysis the 30 000 one time recipients of an NSAID prescription during [1987] [1988] . When these patients' data were kept in the analysis, the rate ratio was 1 7, not 1 5. Thus the exclusion did not change the interpretation of the study.
Discussion
The results of our study show 
